Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Neurology, Gastrointestinal, Multiple Sclerosis |
| Therapuetic Areas: | Gastroenterology, Neurology, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | March 2010 |
| Contact: | Christopher Eckstein, MD |
| Email: | eckstein@jhmi.edu |
| Phone: | (410) 502-1937 |
A Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple Sclerosis
The purpose of this study is to determine the safety and the immunologic effects of
supplementation with low-dose and high-dose cholecalciferol (vitamin D3) in patients with
multiple sclerosis.
Inclusion Criteria:
- Between ages of 18-55 years (inclusive)
- Serum 25(OH) vitamin D levels between 20-50 ng/mL and a candidate for vitamin D
supplementation
- Patients with or without immunomodulatory therapy for RRMS
- Diagnosis of multiple sclerosis
Exclusion Criteria:
- Serum 25(OH) vitamin D deficient level < 20 ng/mL
- High dose vitamin D supplementation in the past 3 months
- Pregnancy
- History of tuberculosis, hyperparathyroidism, sarcoidosis or kidney stones
- Baseline serum creatinine above 1.5
- Hypersensitivity to vitamin D preparations
- Milk allergy
- Unable to consent
We found this trial at
1
site
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
